Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
Axsome Therapeutics (AXSM) Tops Q1 EPS by $1.03; Offers Operational Guidance
May 8, 2023 7:05 AM EDTAxsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($0.26), $1.03 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $25.2 million.
Axsome believes that its current cash, along with the remaining committed capital from the $350... More
